Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group
Yousif Matloub(Roswell Park Comprehensive Cancer Center), Paul S. Gaynon(University of Southern California), Gregory Reaman(American Society of Clinical Oncology), Stephen P. Hunger(Children's Hospital of Philadelphia), Naomi Winick(Universität Hamburg), Anne Angiolillo(Children's National), Catherine Cole(Maine Medical Center), Patrick J. Buckley(Duke Medical Center), William L. Carroll(NYU Langone Health), Meenakshi Devidas(National Institutes of Health), Linda C. Stork(Oregon Health & Science University), Mei La(Arcadia), Blythe Thomson(Epizyme (United States)), Scott L. Sailer(Waverly Hematology Oncology), Nyla A. Heerema(The Ohio State University), James B. Nachman(University of Chicago), Bruce Bostrom(Minnesota West Community & Technical College), Harland N. Sather(Children's Oncology Group), Julie M. Gastier‐Foster(Nationwide Children's Hospital)
Cited by 148
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k